Kineta announced that it has entered into an exclusive option and license agreement with Genentech to develop Kineta's α9/α10 nicotinic acetylcholine receptor antagonists for the treatment of chronic pain.
Frontage Laboratories, Inc., a global contract research organisation (CRO), announced the acquisition of Concord Biosciences (Cleveland, USA) formerly known as Ricerca Biosciences, LLC, a preclinical CRO.
Rhythm Pharmaceuticals, a biopharmaceutical company, announced that it has acquired exclusive, worldwide rights from Takeda Pharmaceutical Company to develop and commercialize a rare genetic disorder drug.
Biologists from Kazan have developed a new drug capable of suppressing myasthenia (muscle weakness) without inducing strong side effects. The scientists tested new drug in rats and human bladder tissue samples.
A team led by Associate Professor John Miles from James Cook University and Cardiff University’s Professor Andrew Sewell describe how they engineered a new vaccine production platform and built a fully synthetic flu vaccine.
Bavarian Nordic announced the signing of a new alliance with the US Department of Defense for the development of a prophylactic vaccine against the equine encephalitis virus—a rare, but potentially deadly mosquito-borne illness.
Citoxlab Group, a leading non-clinical CRO, entered into a definitive agreement to acquire Solvo Biotechnology, a CRO specializing in drug transporter studies and the assessment of Drug-Drug Interactions.
BioNeuroPharma, a participant of SKOLKOVO biomed cluster, reached an agreement with the Cuban Neuroscience Center (CNEURO) on collaboration in the development of potential drugs for treatment of Alzheimer's disease.
The scientists from the Siberian State Medical University are completing the preclinical studies of a unique drug that normalizes the liver detox function and has no obvious undesirable pharmacological properties
A laboratory for early studies of pharmaceuticals intended to treat cancer will be opened in the city of Obninsk, Kaluga region. It will allow to accelerate the market launch of the modern drugs manuf...